FIG 3.
HR for palbociclib intake duration (≥ or < the given landmark) up to 6, 12, 18, and 24 months (HR < 1 suggests that longer palbociclib duration is associated with improved iDFS). HR, hazard ratio; iDFS, invasive disease-free survival.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.